File download
Send files
Remove all

Admescope Blog

CYP induction assays – which way to go?

5 September 2018

In drug discovery and development, there are often several options available for addressing research questions, which may vary considerably in laboriousness, costs and the level of data they produce. Therefore, it is important to choose the right study set up at the right time to obtain correct and relevant answers for the project. As an example of different study approaches, let’s have a look at alternatives for studying CYP enzyme induction in vitro.
Read more
Tags: , DDI

The new FDA draft guidance on DDI studies – how does it affect in vitro studies?

1 December 2017

Recently FDA released new draft guidance on drug-drug interaction (DDI) studies. Compared to the previous one issued in 2012, also the structure is revised as there is now two complementary documents. The “In Vitro Metabolism- and Transporter –Mediated Drug-Drug Interaction Studies” focuses on in vitro approaches to evaluate potential interaction risk,
Read more
Tags: , ADME, DDI, Transporters

ADME-Tox e-books – why are we doing these?

16 August 2017

Working at a CRO is not only about providing research services, but also about helping and supporting customers in different ways throughout the process. We have the pleasure to work with a wide variety of customers, ranging from small biotech and academic research groups to Big Pharma companies.
Read more

HR-MS – when does it make a difference?

6 June 2017

In addition to knowledge and knowhow regarding the early phase ADME studies, also the analytical instrumentation applied plays a big role in their success. The importance of using liquid chromatography coupled to high resolution mass spectrometry (LC/HR-MS) in drug discovery and preclinical phase ADME studies has been emphasized for few years, but when does it really make a difference? To elucidate the topic further, we interviewed an expert in the field, Dr Ari Tolonen.
Read more